Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04374019 · ClinicalTrials.gov registry record · Phase 2
Novel Agents for Treatment of High-risk COVID-19 Positive Patients
A Phase 2 study, sponsored by Susanne Arnold.
- Terminated
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT04374019: Clinical Trial Phase 2 study, sponsored by Susanne Arnold.
NCT04374019 is a Phase 2 study that was terminated before completion, run by Susanne Arnold. The registered enrollment target is 13 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04374019, a Phase 2 study, was terminated before completion, sponsored by Susanne Arnold.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
This is a multi-arm, phase II trial for rapid efficacy and toxicity assessment of multiple therapies immediately after COVID19 positive testing in high-risk individuals. Therapies include stand-alone or combination treatment with hydroxychloroquine, azithromycin, ivermectin, or camostat mesilate, artemesia annua. The hypothesis of this study is that the addition of agents that inhibit viral entry or replication of SARS-CoV-2 virus replication in will be devoid of additional moderate to severe toxicities, will prevent clinical deterioration, and will improve viral clearance in high risk individuals.
Primary Outcome
Number of patients experiencing clinical deterioration. Clinical deterioration is defined as a less than a 2-point change from the initial COVID 7-Point Ordinal Outcomes Scale within 14 days from the study start. This scale ranges from 1-7. Lower scores indicate worse outcomes (death); higher scores indicate fewer symptoms and better outcomes.
Interventions
- DRUG Ivermectin
- DRUG Artesunate
- DRUG Camostat Mesilate
- DIETARY_SUPPLEMENT Artemesia annua
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2020-05-01 |
| Est. Completion | 2022-01-12 |
| Phase | Phase 2 |
Why NCT04374019 stopped before completion
NCT04374019 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 4 interventions - of which Ivermectin is the first listed.
NCT04374019 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04374019 about?
NCT04374019 is a clinical study titled "Novel Agents for Treatment of High-risk COVID-19 Positive Patients". This is a multi-arm, phase II trial for rapid efficacy and toxicity assessment of multiple therapies immediately after COVID19 positive testing in high-risk individuals. Therapies include stand-alone or combination treatment with hydroxychloroquine, azithromycin, ivermectin, or camostat mesilate, ar...
What is the current status of trial NCT04374019?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2020-05-01. Estimated completion is 2022-01-12.
What interventions are being tested in trial NCT04374019?
The interventions under investigation include: Ivermectin (DRUG), Artesunate (DRUG), Camostat Mesilate (DRUG), Artemesia annua (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04374019?
This trial is sponsored by Susanne Arnold, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04374019's enrollment target sits among peer trials
13 1947th of 2000 higher than 53 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI